Kindler joins Blackstone as senior adviser; plus changes at Mission, Annexon, Dyne, Ribometrix, Autolus and more

Jeffrey Kindler has joined Blackstone Group as a senior adviser. He is the CEO of Centrexion Therapeutics Corp. and served as chairman and CEO of Pfizer Inc. (NYSE:PFE) in 2006-10.

Mission Therapeutics Ltd. promoted Paul Thompson to CSO from VP of clinical development. The biotech also promoted Nick Edmunds to CTO from VP and head of deubiquitylating enzyme (DUB) discovery. The company is developing small molecule inhibitors of DUBs to treat fibrosis as well as kidney, neurodegenerative and mitochondrial diseases...